Zogenix rockets up as PhIII study offers impressive data on Dravet syndrome, vaulting over a rival
Zogenix offered investors exactly the kind of gourmet data they were looking for this morning with a clean sweep of promising data for its late …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
